VSTM vs ZBIO Stock Comparison

VSTM currently leads ZBIO in this stock comparison, with AIQ scores of 60 vs 47. The clearest difference is value.

Market data as of Nov 15, 2026 market close· AIQ score gap 13 points
VSTM
Healthcare
vs
ZBIO
Healthcare
VSTM
Verastem, Inc.
Leads
Price
$8.18
Day move
-3.08%
AIQ Score
60/100
Best edge
Value
Sector
Healthcare
ZBIO
Zenas BioPharma, Inc.
Price
$28.01
Day move
+1.34%
AIQ Score
47/100
Best edge
Balanced
Sector
Healthcare

What is the main difference between VSTM and ZBIO?

VSTM leads the current stock comparison as Verastem, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Verastem, Inc. vs Zenas BioPharma, Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 64/66 fields· High confidence
AIQ VerdictCompetitiveAIQ Comparison Conviction 7/10

VSTM leads

VSTM leads by 13 AIQ points, primarily on Value and Quality.

Competitive: 4 of 6 evidence groups support VSTM, and its current signal state is conflicted.

Evidence agreement: 4 of 6Comparison trend: Stable
VSTM

Verastem, Inc.

Leads
AIQ Score
60/100
AIQ Edge Score
6/10
ZBIO

Zenas BioPharma, Inc.

AIQ Score
47/100
AIQ Edge Score
4/10

The Algovestiq AIQ Score currently favors VSTM over ZBIO, 60 versus 47 as of Nov 15, 2026. VSTM's advantage is driven primarily by stronger value and quality. VSTM also shows the weaker technical structure relative to its 50-day moving average. 4 of 6 covered evidence groups favor VSTM today, and the comparison is rated Competitive on stability: the leader is throwing conflicting signals. VSTM lead: Stable — the AIQ differential has held near 13 points over 30 sessions.

Compare Verastem, Inc. and Zenas BioPharma, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

VSTM
+191.1%
ZBIO
+54.3%

Price return comparison

Growth of $10,000, price only

VSTM $29,110 · ZBIO $15,433

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare VSTM and ZBIO against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

VSTM advantage
0
ZBIO advantage
  • Value53 vs 33
    VSTM +20
  • Quality42 vs 25
    VSTM +17
  • Momentum89 vs 78
    VSTM +11
  • Risk Resilience36 vs 39
    Even

4 of 6 evidence groups favor VSTM. VSTM’s edge is concentrated in value and quality.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

VSTM0 AIQ

Largest factor move: Momentum -2, not enough on its own to move the overall score.

No signal started or stopped since the prior session; its 4 active signals are unchanged.

ZBIO+1 AIQ

Largest factor move: Momentum +2

New signals

  • Beta Spike Warning — bearish, risk_regime, long horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.61x)
  • RSI Midline Reclaim — bullish, momentum, short horizon

VSTM's lead narrowed by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — VSTM and ZBIO both carry a full feed there.

The central trade-off

VSTM (Verastem, Inc.): the stronger current systematic profile, led by value and quality.

ZBIO (Zenas BioPharma, Inc.): the counter-case, on fundamentals.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

VSTM

VSTM on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

ZBIO

ZBIO on combined revenue and EPS growth.

Value

VSTM

VSTM on the peer-relative Value factor, by 20 points.

Momentum

VSTM

VSTM on the Momentum factor, by 11 points.

Lower downside

ZBIO

ZBIO carries the lower 1-month annualized volatility.

Analyst upside

VSTM

VSTM on implied upside to the consensus price target.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureVSTMZBIONote
Implied upside to target+126.2%+96.4%VSTM has more room
Target dispersion+48.6%0%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering108Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

4 of 6 covered evidence groups favor VSTM. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreVSTM60 vs 47
FundamentalsZBIOon balancerevenue growth -40.1% vs 9%; EPS growth -111.4% vs 6.8%; TTM ROE -7.4% vs -51.3%; gross margin 86.1% vs -6.6%; operating margin -193.7% vs -47.9% — ZBIO takes 3 of 5 decided legs, not all of them
ValuationVSTMValue 53 vs 33
TechnicalsVSTMPrice vs 50-day -3.6% vs -2%; vs 200-day 29.9% vs 10.5%
Risk ResilienceEvenRisk Resilience 36 vs 39
Analyst expectationsVSTMTarget upside 126.2% vs 96.4%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of VSTM and ZBIO and are excluded from the count.

AIQ Decision Stability

Competitive

The two are close enough that your objective, not the score, should decide.

  • The AIQ gap is wide at 13 points. (supports the conclusion holding)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on VSTM.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

VSTM lead: Stable — the AIQ differential has held near 13 points over 30 sessions.

May 27VSTM leads above the line · ZBIO leads belowNov 13
Today
VSTM +13
60 vs 47
7 sessions ago
VSTM +14
60 vs 46
30 sessions ago
VSTM +14
57 vs 43
90 sessions ago
VSTM +6
51 vs 45

The lead changed hands 2 times in this window, most recently on Aug 13 when VSTM moved ahead of ZBIO.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

VSTMConflicted

2 bullish / 1 bearish / 1 neutral, conflicted

Only VSTM

  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
ZBIOConflicted

3 bullish / 2 bearish / 1 neutral, conflicted

Only ZBIO

  • Beta Spike Warning — bearish, risk_regime, long horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.61x)
  • RSI Midline Reclaim — bullish, momentum, short horizon

Both carry 3 more signals that do not separate them: Golden Cross Active, ATR Expansion - Breakout Mode, EMA Ribbon Expansion Bullish.

VSTM leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

VSTMNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -3.08%, AIQ 0 points).

ZBIOConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +1.34%, AIQ +1 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1ZBIO closes the Value gap — currently 20 points behind, the largest single contributor to VSTM's edge.
  2. 2ZBIO's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
  3. 3VSTM's conflicting signal state resolves bearish — it currently carries 2 bullish and 1 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

ZBIO leads on balance
MetricVSTMZBIO
Revenue growth (YoY)-40.1%9%
EPS growth (YoY)-111.4%6.8%
Gross margin86.1%-6.6%
Operating margin-193.7%-47.9%
Return on equity (TTM)-7.4%-51.3%
Debt to equity12.091.42

Performance

VSTM leads 4 of 6 windows
MetricVSTMZBIO
1 week (5 sessions)-2.7%-0.9%
1 month (20 sessions)-5.4%12.8%
3 months (63 sessions)13.9%-8.2%
6 months (126 sessions)89.4%52.7%
Year to date6%-22.9%
1 year (252 sessions)-3.9%-21.8%

Technicals

VSTM has the stronger structure
MetricVSTMZBIO
RSI (14)41.650.1
ADX (14)28.312.2
Price vs 50-day-3.6%-2%
Price vs 200-day29.9%10.5%
Volatility (1M, annualized)72.4%65.7%

Risk

Split
MetricVSTMZBIO
Beta0.890.75
Sharpe ratio0.320.26
Sortino ratio0.490.34
Max drawdown-67.6%-64.8%
Current drawdown-23.1%-35.1%
Annualized volatility74.2%95.3%
Value at risk (95%)-7.2%-7.3%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, VSTM or ZBIO?

On the Algovestiq AIQ Score, VSTM is the stronger of the two as of Nov 15, 2026, scoring 60 against ZBIO's 47. The edge comes from value and quality. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is VSTM or ZBIO the better buy right now?

VSTM carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Competitive — 4 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.

Why does the AIQ Score favor VSTM over ZBIO?

The composite weights Quality, Value, Momentum and Risk Resilience. VSTM leads Value by 20 points; VSTM leads Quality by 17 points; VSTM leads Momentum by 11 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, VSTM or ZBIO?

Analyst price targets imply +126.2% upside for VSTM and +96.4% for ZBIO, so the Street currently favors VSTM. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, VSTM or ZBIO?

VSTM is the better-valued of the two on the peer-relative Value factor. VSTM on the peer-relative Value factor, by 20 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, VSTM or ZBIO?

ZBIO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, VSTM or ZBIO?

VSTM on the Momentum factor, by 11 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, VSTM or ZBIO?

ZBIO is the more resilient of the two, so the other name carries the higher downside risk. ZBIO carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is VSTM more profitable than ZBIO?

The profitability evidence is mixed: gross margin 86.1% vs -6.6%; operating margin -193.7% vs -47.9%; ttm roe -7.4% vs -51.3%. VSTM leads on two measures and ZBIO on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is VSTM's lead over ZBIO getting stronger or weaker?

VSTM lead: Stable — the AIQ differential has held near 13 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands 2 times in that window, most recently on 2026-08-13, when VSTM moved ahead of ZBIO.

What would change the VSTM vs ZBIO verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: ZBIO closes the Value gap — currently 20 points behind, the largest single contributor to VSTM's edge; ZBIO's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; VSTM's conflicting signal state resolves bearish — it currently carries 2 bullish and 1 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about VSTM and ZBIO?

VSTM: 2 bullish / 1 bearish / 1 neutral, conflicted. ZBIO: 3 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on VSTM is Golden Cross Active (bullish, long horizon). On ZBIO it is Golden Cross Active (bullish, long horizon).

Compare VSTM and ZBIO with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.